Literature DB >> 329981

Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.

L H Einhorn, B Furnas.   

Abstract

Thirty patients with disseminated melanoma were treated with DTIC (250 mg/m2 for 5 consecutive days every 3 weeks), methyl-CCNU (175 mg/m2 orally every 6 weeks), and vincristine (1.4 mg/m2 weekly x 6 and then every 3 weeks). Seven patients died within 3 weeks of the start of chemotherapy. There was a 30% response rate (seven partial and two complete remissions) for all patients and a 39% response for evaluable patients. The median survival was 45 and 18 weeks respectively for responders versus non-responders and 22 weeks for all evaluable patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 329981

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

Review 1.  Chemotherapy of malignant melanoma.

Authors:  R S Benjamin
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 2.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

3.  Vindesine. A short review of preclinical and first clinical data.

Authors:  R W Dyke; R L Nelson; W P Brade
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Vindesine as a single agent in the treatment of advanced malignant melanoma.

Authors:  S Retsas; K A Newton; G Westbury
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.